biological sampling
Procedurecutaneous, rectal, nose and mouth swabs to identify potential fungi colonization
NCT Number: NCT01770015
Ventilator acquired pneumonia (VAP) are severe nosocomial infections. On the other side, bronchial fungi colonization is commonly observed in ICU; therefore, the investigators propose to study the role of bronchial fungi colonization on the occurrence of VAP taking into account the immune status of the patient and the antibiotic and antifungal treatments he has received.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Hospital University Clermont Ferrand Gabriel Montpied, Clermont-Ferrand, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
cutaneous, rectal, nose and mouth swabs to identify potential fungi colonization
HLA DR antigen, cytokines (IL 6 and 10), B-glucan
fungi and bacteria endotracheal aspiration
Time frame: Participants will be followed for the duration of mechanical ventilation, an expected time frame that can go from 5 days to up to 8 weeks
Time frame: Participants will be followed for the duration of mechanical ventilation, an expected time frame that can go from 5 days to up to 8 weeks
Time frame: Participants will be followed for the duration of mechanical ventilation, an expected time frame that can go from 5 days to up to 8 weeks
University Hospital, Grenoble
Other
Study of the Impact of Bronchial Colonization With Fungi in the Occurrence of Late Ventilator Acquired Pneumonia
Acronym: CBF et PAVMt
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06867458
Cross Infection, Disease Attributes
New Westminster, British Columbia, Canada
View Trial DetailsNCT07001163
Cross Infection, Disease Attributes
Tanta, Q2x2+cp Tanta 2, Egypt,, Egypt
View Trial DetailsNCT06592547
Cross Infection, Disease Attributes
Alexandria, Egypt
View Trial DetailsNCT00938002
Cross Infection, Disease Attributes
Denver, Colorado, United States
View Trial Details